Results 71 to 80 of about 6,532 (197)
Magnetochemistry, 2020 Magnetic nanoparticles have been largely applied to increase the efficacy of antibiotics due to passive accumulation provided by enhancing permeability and retention, which is essential for the treatment of lung infections. Recurring lung infections such
Marsha Tan +2 more
doaj +1 more source
Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview [PDF]
MedComm (2020)The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Lele M +7 more
europepmc +2 more sources
Elexacaftor–Tezacaftor–Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis
The Laryngoscope, Volume 136, Issue 5, Page 2048-2053, May 2026.Elexacaftor–tezacaftor–ivacaftor (ETI) was associated with a significant decrease in the frequency and rate of endoscopic sinus surgeries in patients with cystic fibrosis. These findings suggest an improvement in CF‐related chronic rhinosinusitis outcomes following ETI and may influence future CF treatment decisions.
Amy Lin +6 more
wiley +1 more source
Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
, 2013 Ruth O'Reilly, Heather E Elphick Sheffield Children's Hospital, Western Bank, Sheffield, United Kingdom Abstract: Cystic fibrosis (CF) is a life-limiting, multisystem disease characterized by thick viscous secretions leading to recurrent lung ...
O’Reilly R, Elphick HE
core
Challenges to Assessing the Prevalence of Cystic Fibrosis in the Caribbean
Pediatric Pulmonology, Volume 61, Issue 5, May 2026.ABSTRACT Cystic fibrosis (CF) is likely underdiagnosed in Caribbean populations due to non‐representative cystic fibrosis transmembrane conductance regulator (CFTR) variant screening panels, limited newborn screening programs, and structural healthcare barriers.
Krystal L. Rivera‐Figueroa +5 more
wiley +1 more source
, 2021 BACKGROUND: Ivacaftor is currently the only CFTR potentiator approved and is increasingly used since the development of CFTR correctors. Ivacaftor is metabolized by CYP3A4 and therefore dose reduction is required when treating patients on ivacaftor with ...
Richart Sturm +7 more
core +1 more source
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations
, 2020 Background: Tezacaftor/ivacaftor is a CFTR modulator approved to treat people with cystic fibrosis (pwCF) who are homozygous (F/F) or heterozygous for the F508del-CFTR mutation and a residual function mutation (F/RF).
Campbell, Daniel +7 more
core +1 more source
Pediatric Pulmonology, Volume 61, Issue 5, May 2026.ABSTRACT Rationale Cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) are characterized by neutrophilic airway inflammation but differ in clinical features. Objectives We investigated relationships of pulmonary and systemic inflammatory markers with functional and structural lung disease.
Teresa Fuchs +9 more
wiley +1 more source
The Pharmacokinetic Interaction between Ivacaftor and Ritonavir
, 2019 Ivacaftor is the first small molecule for the treatment of cystic fibrosis (CF) that directly targets the inherited defect in the cystic fibrosis transmembrane conductance regulator (CFTR).
LIDDY, ANNE MARIE
core
Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)
, 2017 Ivacaftor is a potentiator of the CFTR chloride channel and is in worldwide clinical use for the chronic treatment of cystic fibrosis in patients. There is evidence that the bioavailability of ivacaftor in the body may be influenced by the multi-drug ...
Thonghin, Nopnithi +5 more
core +1 more source